Search for: "Tris Pharma Inc."
Results 1 - 20
of 125
Sort by Relevance
|
Sort by Date
17 May 2024, 1:07 pm
Police arrive, vehicle tries to leave, police conduct a Terry stop, and they discover the gun. [read post]
6 Dec 2022, 4:50 pm
Astellas Pharma US, Inc., Circuit Court of Cook County, Illinois County Dept., Chancery Div., 2019 CH 14483 (Nov. 28, 2022). [read post]
4 Oct 2022, 1:10 pm
Kite Pharma, Inc. concerns the test for determining whether the “written description of [an] invention” is so inadequate as to render a patent invalid. [read post]
26 Sep 2022, 4:49 am
Kite Pharma, Inc., No. 21-1566 According to the Federal Circuit, US patent law contains separate and distinct written description and enablement requirements. [read post]
19 Jul 2022, 2:59 pm
BioMimetic Therapeutics, Inc., 2013 WL 139521, at *13-14 (M.D. [read post]
14 Jul 2022, 9:55 pm
Noonan -- Almost four years ago, in a relatively rare occurrence based on there being an insufficient factual record to permit proper appellate review, the Federal Circuit vacated a District Court decision rendering invalid the claims in five patents asserted by Tris Pharma, Inc. against Teva Laboratories FL, Inc. and remanded. [read post]
8 Jul 2022, 3:47 am
Tris Pharma, Inc. v. [read post]
25 May 2022, 1:57 pm
Background Cocrystal Pharma, Inc. was formed in April 2014 through a reverse merger that took place between Biozone Pharmaceuticals and Cocrystal Discovery. [read post]
23 May 2022, 8:02 am
” “The latest word from the Delaware court came Tuesday in Novartis’ bid to disqualify Chidambaram Iyer of Sughrue Mion PLLC from representing Shilpa Pharma Inc., the Pennsylvania arm of a generic drugmaker based in Raichur, India. [read post]
13 Mar 2022, 9:41 am
Back in 2015, Wu-Tang Clan produced Once Upon a Time in Shaolin, but they only produced one copy and sold it to the highest bidder: pharma-bro Martin Shkreli, who was later convicted of securities fraud. [read post]
9 Nov 2021, 5:04 pm
On November 9, the Department of Justice announced that Virginia-based pharmaceutical manufacturer Kaleo, Inc., has agreed to pay $12.7 million to settle fraud allegations, originally brought by a whistleblower, that the company steered physicians’ prescriptions to pharmacies kaléo Inc., a Virginia-based pharmaceutical manufacturer, has agreed to pay the United States $12.7 million to resolve allegations that kaléo caused the submission of false claims for… [read post]
12 Oct 2021, 5:12 pm
Appendix to the HTSUS (“USITC Pharma. [read post]
26 Apr 2021, 3:32 am
Gilead Sciences, Inc. v. [read post]
21 Apr 2020, 6:30 am
In Valeant Pharmaceuticals International, Inc. v. [read post]
20 Oct 2019, 5:58 am
State Attorney General tried to do this through its lawsuit in Suffolk County N.Y. against the Sackler family and Purdue Pharma. [read post]
31 Aug 2019, 8:25 am
” Johnson & Johnson Vows to Fight Back As is their tradition, Johnson & Johnson, the $350-billion-dollar Big Pharma company, plans to appeal the Oklahoma judgement. [read post]
24 May 2019, 10:46 pm
The $100,000 payment Medical Informatics Engineering, Inc. [read post]
6 May 2019, 5:44 pm
Health plans, their sponsoring employers and unions, insurers, fiduciaries, administrators, insurers and other service providers should learn from the $3 million lesson a Franklin, Tennessee-based diagnostic medical imaging services provider is learning about the heavy penalties a health plan, health care provider, health care clearinghouse or business associate (“Covered Entity”) risks if a post-data breach investigation by the U.S. [read post]
30 Apr 2019, 10:23 am
Health plans must deliver electronic protected health information (“ePHI”) to electronic applications or software (“apps”) used by plan members, and are responsible under the Health Insurance Portability & Accountability Act (“HIPAA”) Privacy and Security Rules for the security of electronic protected health information (“ePHI”) on apps they sponsor or provide, according to new guidance from the Department of Health & Human Services… [read post]
31 Mar 2019, 7:48 pm
Sandoz, Inc.), the Federal Circuit has increased the quantum of explanation it requires from district courts (and the Patent Trial and Appeal Board even more frequently) in reviewing questions of fact for clear error (see, e.g., Tris Pharma, Inc. v. [read post]